PMID- 23346316
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130125
LR  - 20240407
IS  - 2005-0380 (Print)
IS  - 2005-0399 (Electronic)
IS  - 2005-0380 (Linking)
VI  - 24
IP  - 1
DP  - 2013 Jan
TI  - Major clinical research advances in gynecologic cancer in 2012.
PG  - 66-82
LID - 10.3802/jgo.2013.24.1.66 [doi]
AB  - Ten topics were chosen among major clinical research achievements in gynecologic 
      oncology in 2012. For ovarian cancer, comprehensive review of the history of 
      bevacizumab studies was followed by poly adenosine diphosphate [ADP]-ribose 
      polymerase (PARP) inhibitors and other molecular targeted agents such as 
      epidermal growth factor receptor tyrosine kinase inhibitor and AMG 386. For the 
      development of genomic study in gynecologic cancers, BRCA and DICER1 mutations 
      were covered in epithelial and nonepithelial ovarian cancer, respectively. For 
      endometrial cancer, targeted agents including mammalian target of rapamycin 
      (mTOR) inhibitors and bevacizumab were discussed. Radiation therapy "sandwiched" 
      between combination chemotherapy schedules for the treatment of uterine papillary 
      serous carcinoma was also reviewed. Preoperative prediction of lymph node 
      metastasis, definition of low-risk group, and recurrence and survival outcomes of 
      laparoscopic approaches were addressed. For cervical cancer, we reviewed 
      long-term benefit of human papillomavirus test and efficacy of 
      paclitaxel/carboplatin versus paclitaxel/cisplatin in stage IVB, persistent or 
      recurrent disease. In addition, the effect of three dimensional image-based 
      high-dose rate brachytherapy was also reviewed. For vulvar cancer, the diagnostic 
      value of sentinel lymph node biopsy was discussed. For breast cancer, positive 
      results of three outstanding phase III randomized clinical trials, CLEOPATRA, 
      EMILIA, and BOLERO-2 were introduced. Lastly, updates of major practice 
      guidelines were summarized.
FAU - Suh, Dong Hoon
AU  - Suh DH
AD  - Department of Obstetrics and Gynecology, Seoul National University College of 
      Medicine, Seoul, Korea.
FAU - Kim, Jae-Weon
AU  - Kim JW
FAU - Kim, Kidong
AU  - Kim K
FAU - Kim, Hak Jae
AU  - Kim HJ
FAU - Lee, Kyung-Hun
AU  - Lee KH
LA  - eng
PT  - Journal Article
DEP - 20130108
PL  - Korea (South)
TA  - J Gynecol Oncol
JT  - Journal of gynecologic oncology
JID - 101483150
PMC - PMC3549510
OTO - NOTNLM
OT  - Bevacizumab
OT  - Image-based high-dose rate brachytherapy
OT  - Low-risk endometrial cancer
OT  - PARP inhibitor
OT  - Practice guidelines
COIS- No potential conflict of interest relevant to this article was reported.
EDAT- 2013/01/25 06:00
MHDA- 2013/01/25 06:01
PMCR- 2013/01/01
CRDT- 2013/01/25 06:00
PHST- 2012/12/31 00:00 [received]
PHST- 2013/01/02 00:00 [accepted]
PHST- 2013/01/25 06:00 [entrez]
PHST- 2013/01/25 06:00 [pubmed]
PHST- 2013/01/25 06:01 [medline]
PHST- 2013/01/01 00:00 [pmc-release]
AID - 10.3802/jgo.2013.24.1.66 [doi]
PST - ppublish
SO  - J Gynecol Oncol. 2013 Jan;24(1):66-82. doi: 10.3802/jgo.2013.24.1.66. Epub 2013 
      Jan 8.